Systematic Investigation of the Effects of Long-Term Administration of a High-Fat Diet on Drug Transporters in the Mouse Liver, Kidney and Intestine

Author(s): Xianyuan Lu, Yaqian Dong, Zhichao Jian, Qingyun Li, Linna Gong, Lan Tang, Xuefeng Zhou*, Menghua Liu*.

Journal Name: Current Drug Metabolism

Volume 20 , Issue 9 , 2019


Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Long-term intake of a high-fat diet is a crucial factor contributing to obesity, which has become a global public health problem. Progressive obesity subsequently leads to hepatic injury, renal damage and intestinal atrophy. Transporters expressed in the liver, kidney and intestine play important roles in the deposition of nutrients and drugs, but researchers have not clearly determined whether/how the expression of transporters changes after long-term administration of a High-Fat Diet (HFD). This study aims to explore the effects of the long-term administration of a HFD on the expression of drug transporters in the liver, kidney and intestine in mice and to provide useful information for medical applications in the clinic.

Methods: Male C57BL/6J mice were fed either a basal diet or HFD for 24 weeks, and oral glucose tolerance tests were performed after 3, 11 and 23 weeks. Serum was obtained to measure lipid metabolism, inflammatory mediators, renal function and hepatic function. Adipose tissues, kidney, pancreas and liver were collected for hematoxylin and eosin (H&E) staining after 4, 12 and 24 weeks. The mRNA and proteins expression of drug transporters in the liver, kidney and intestine were detected using real-time PCR and western blot, respectively.

Results: Compared with the control group, long-term HFD administration significantly increased the adipose index. The serum lipid levels, including Total Cholesterol (TC), Triglyceride (TG), and Low-Density Lipoprotein Cholesterol (LDL-C), as well as the levels of the inflammatory cytokines Interleukin-10 (IL-10) and tumor necrosis factor-α (TNF-α) were significantly elevated in HFD-induced obese mice. H&E staining revealed pathological changes in the adipose cells, liver, kidney and pancreas from the obese group following the long-term administration of the HFD. The liver of the obese group presented increased mRNA expression of the efflux transporter Mrp2 and uptake transporter Oat2 at 24 weeks. The relative expression of Oat2 increased 4.08-fold and the protein expression of Oat2 was upregulated at 24 weeks in HFD-fed mice, while the mRNA expression of the uptake transporters Oct1, Oatp1b2 and Oatp1a4 decreased by 79%, 61% and 19%, respectively. The protein expression of Oct1 was significantly downregulated in obese mice at 12 weeks. The mRNA expression of the efflux transporter Mdr1a was significantly reduced in HFD-fed mice compared with the control group at 24 weeks. Western blot showed that the trend of protein level of Mdr1 was consistent with the mRNA expression. In the kidney, the level of the Oct2 mRNA increased 1.92- and 2.46-fold at 4 and 12 weeks in HFD-fed mice, respectively. The expression of the Oat1 and Oat3 mRNAs was markedly downregulated in the kidneys of mice with HFD-induced obesity at 4 weeks. The decrease of 72% and 21% in Mdr1a mRNA expression was observed in the obese model at 4 weeks and 12 weeks, respectively. Western blot showed that the protein levels of Mdr1 and Oat1 were consistent with the mRNA expression. The qPCR experiments showed a 2.87-fold increase in Bcrp mRNA expression at 24 weeks, and the expression of the Pept1 mRNA increased 2.84-fold in intestines of obese mice subjected to long-term administration of the HFD compared with control mice at 12 weeks. Western blot showed that the trend of protein levels of Mdr1 and Mrp2 were consistent with the mRNA expression.

Conclusion: The expression of uptake and efflux transporters mRNAs and protein levels were altered in obese mice compared with control mice, providing scientific evidence for future medical applications in the clinic.

Keywords: High-fat Diet (HFD), obesity, lipid metabolism, inflammatory mediators, uptake drug transporters, efflux drug transporters.

[1]
Sid, V.; Siow, Y.L.; Shang, Y.; Woo, C.W. O, K. High-fat diet consumption reduces hepatic folate transporter expression via nuclear respiratory factor-1. J. Mol. Med. (Berl.), 2018, 96(11), 1203-1213.
[http://dx.doi.org/10.1007/s00109-018-1688-8] [PMID: 30178194]
[2]
Han, L.; Shen, W.J.; Bittner, S.; Kraemer, F.B.; Azhar, S. PPARs: Regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α. Future Cardiol., 2017, 13(3), 259-278.
[http://dx.doi.org/10.2217/fca-2016-0059] [PMID: 28581332]
[3]
Jun, Z.; Benoit, C.; Vishal, S.; Michael, D.F.; Matam, V.K.; Andrew, T.G. Fiber-mediated nourishment of gut microbiota potects against diet-induced obesity by restoring IL-22-mediated colonic health. Cell Host Microbe, 2018, 23, 41-53.
[http://dx.doi.org/10.1016/j.chom.2017.11.003] [PMID: 29276170]
[4]
Jung, Y.C.; Kim, H.W.; Min, B.K.; Cho, J.Y.; Son, H.J.; Lee, J.Y.; Kim, J.Y.; Kwon, S.B.; Li, Q.; Lee, H.W. Inhibitory effect of olive leaf extract on obesity in high-fat diet-induced mice. In Vivo, 2019, 33(3), 707-715.
[http://dx.doi.org/10.21873/invivo.11529] [PMID: 31028187]
[5]
Navarro, C.D.C.; Figueira, T.R.; Francisco, A.; Dal’Bó, G.A.; Ronchi, J.A.; Rovani, J.C.; Escanhoela, C.A.F.; Oliveira, H.C.F.; Castilho, R.F.; Vercesi, A.E.; Vercesi, A.E. Redox imbalance due to the loss of mitochondrial NAD(P)-transhydrogenase markedly aggravates high fat diet-induced fatty liver disease in mice. Free Radic. Biol. Med., 2017, 113, 190-202.
[http://dx.doi.org/10.1016/j.freeradbiomed.2017.09.026] [PMID: 28964917]
[6]
Xu, Y.J.; Wang, Y.; Lu, Y.F.; Xu, S.F.; Wu, Q.; Liu, J. Age-associated differences in transporter gene expression in kidneys of male rats. Mol. Med. Rep., 2017, 15(1), 474-482.
[http://dx.doi.org/10.3892/mmr.2016.5970] [PMID: 27909713]
[7]
Dong, Y.; Van Der Walt, N.; Pennington, K.A.; Yallampalli, C. Impact of adrenomedullin blockage on lipid metabolism in female mice exposed to high-fat diet. Endocrine, 2019, 65(2), 278-285.
[http://dx.doi.org/10.1007/s12020-019-01927-8] [PMID: 31025262]
[8]
Liu, B.; Luo, F.; Luo, X.; Duan, S.; Gong, Z.; Peng, J. Metabolic enzyme system and transport pathways in chronic kidney diseases. Curr. Drug Metab., 2018, 19(7), 568-576.
[http://dx.doi.org/10.2174/1389200219666180103143448] [PMID: 29299983]
[9]
Noel, G.; Le Vee, M.; Moreau, A.; Stieger, B.; Parmentier, Y.; Fardel, O. Functional expression and regulation of drug transporters in monolayer- and sandwich-cultured mouse hepatocytes. Eur. J. Pharm. Sci., 2013, 49(1), 39-50.
[http://dx.doi.org/10.1016/j.ejps.2013.01.013] [PMID: 23396053]
[10]
Gleb, M.; Kevin, T.B.; Sanjay, K.N. Special section on pediatric drug disposition and pharmacokinetics kidney versus liver specification of SLC and ABC drug transporters, tight junction molecules, and biomarkers. Drug Metab. Dispos., 2016, 44, 1050-1060.
[http://dx.doi.org/10.1124/dmd.115.068254]
[11]
Liu, Y.; Pu, Q.H.; Wu, M.J.; Yu, C. Proteomic analysis for the impact of hypercholesterolemia on expressions of hepatic drug transporters and metabolizing enzymes. Xenobiotica, 2016, 46(10), 940-947.
[http://dx.doi.org/10.3109/00498254.2016.1144228] [PMID: 26887802]
[12]
Patel, M.; Taskar, K.S.; Zamek-Gliszczynski, M.J. Importance of hepatic transporters in clinical disposition of drugs and their metabolites. J. Clin. Pharmacol., 2016, 56(Suppl. 7), S23-S39.
[http://dx.doi.org/10.1002/jcph.671] [PMID: 27385177]
[13]
Xue, Y.; Fan, Z.M. Changes in liver lipid metabolism related genes in mice with high-fat diet non-alcoholic fatty liver disease. Biotechnol. World, 2014, 03, 102-103.
[14]
Xu, T.; Sheng, Z.; Yao, L. Obesity-related glomerulopathy: Pathogenesis, pathologic, clinical characteristics and treatment. Front. Med., 2017, 11(3), 340-348.
[http://dx.doi.org/10.1007/s11684-017-0570-3] [PMID: 28791668]
[15]
Salvatore, S.P.; Chevalier, J.M.; Kuo, S.F.; Audia, P.F.; Seshan, S.V. Kidney disease in patients with obesity: It is not always obesity-related glomerulopathy alone. Obes. Res. Clin. Pract., 2017, 11(5), 597-606.
[http://dx.doi.org/10.1016/j.orcp.2017.04.003] [PMID: 28442280]
[16]
Prasad, B.; Johnson, K.; Billington, S.; Lee, C.; Chung, G.W.; Brown, C.D.; Kelly, E.J.; Himmelfarb, J.; Unadkat, J.D. Abundance of drug transporters in the human kidney cortex as quantified by quantitative targeted proteomics. Drug Metab. Dispos., 2016, 44(12), 1920-1924.
[http://dx.doi.org/10.1124/dmd.116.072066] [PMID: 27621205]
[17]
Rozman, J.; Rathkolb, B.; Neschen, S.; Fuchs, H.; Gailus-Durner, V.; Klingenspor, M.; Wolf, E.; Hrabě de Angelis, M. Glucose tolerance tests for systematic screening of glucose homeostasis in mice. Curr. Protoc. Mouse Biol., 2015, 5(1), 65-84.
[http://dx.doi.org/10.1002/9780470942390.mo140111] [PMID: 25727201]
[18]
Vinué, Á.; González-Navarro, H. Glucose and insulin tolerance tests in the mouse. Methods Mol. Biol., 2015, 1339, 247-254.
[http://dx.doi.org/10.1007/978-1-4939-2929-0_17] [PMID: 26445794]
[19]
Li, A.; Zhang, X.; Shu, M.; Wu, M.; Wang, J.; Zhang, J.; Wang, R.; Li, P.; Wang, Y. Arctigenin suppresses renal interstitial fibrosis in a rat model of obstructive nephropathy. Phytomedicine, 2017, 30, 28-41.
[http://dx.doi.org/10.1016/j.phymed.2017.03.003] [PMID: 28545667]
[20]
Gregory, N.; Marc, L.V.; Amélie, M.; Bruno, S.; Yannick, P.; Olivier, F. Functional expression and regulation of drug transporters in monolayer-and sandwich-cultured mouse hepatocytes. Eur. J. Pharm. Sci., 2013, 2013(49), 39-50.
[21]
Gleb, M.; Kevin, T.B.; Sanjay, K.N. Special section on pediatric drug disposition and pharmacokinetics. kidney versus liver specification of slc and abc drug transporters, tight junction molecules, and biomarker. Drug Metab. Dispos., 2016, 44, 1050-1060.
[http://dx.doi.org/10.1124/dmd.115.068254]
[22]
He, R.; Ai, L.; Zhang, D.; Wan, L.; Zheng, T.; Yin, J.; Lu, H.; Lu, J.; Lu, F.; Liu, F.; Jia, W. Different effect of testosterone and oestrogen on urinary excretion of metformin via regulating OCTs and MATEs expression in the kidney of mice. J. Cell. Mol. Med., 2016, 20(12), 2309-2317.
[http://dx.doi.org/10.1111/jcmm.12922] [PMID: 27469532]
[23]
Engin, A. The definition and prevalence of obesity and metabolic syndrome. Adv. Exp. Med. Biol., 2017, 960, 1-17.
[http://dx.doi.org/10.1007/978-3-319-48382-5_1] [PMID: 28585193]
[24]
Ashwell, M.; Gunn, P.; Gibson, S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: Systematic review and meta-analysis. Obes. Rev., 2012, 13(3), 275-286.
[http://dx.doi.org/10.1111/j.1467-789X.2011.00952.x] [PMID: 22106927]
[25]
Alberti, K.G.M.M.; Zimmet, P.; Shaw, J. The metabolic syndrome-a new worldwide definition. Lancet, 2005, 366(9491), 1059-1062.
[http://dx.doi.org/10.1016/S0140-6736(05)67402-8] [PMID: 16182882]
[26]
Kovesdy, C.P.; Furth, S.L.; Zoccali, C. Obesity and kidney disease: Hidden consequences of the epidemic. Pediatr. Nephrol., 2017, 32(4), 537-545.
[http://dx.doi.org/10.1007/s00467-017-3595-6] [PMID: 28188438]
[27]
Affane, F.; Louala, S.; El Imane Harrat, N.; Bensalah, F.; Chekkal, H.; Allaoui, A.; Lamri-Senhadji, M. Hypolipidemic, antioxidant and antiatherogenic property of sardine by-products proteins in high-fat diet induced obese rats. Life Sci., 2018, 199, 16-22.
[http://dx.doi.org/10.1016/j.lfs.2018.03.001] [PMID: 29505784]
[28]
Duan, X.; Meng, Q.; Wang, C.; Liu, Z.; Sun, H.; Huo, X.; Sun, P.; Ma, X.; Peng, J.; Liu, K. Effects of calycosin against high-fat diet-induced nonalcoholic fatty liver disease in mice. J. Gastroenterol. Hepatol., 2018, 33(2), 533-542.
[http://dx.doi.org/10.1111/jgh.13884] [PMID: 28699662]
[29]
Lu, S.F.; Tang, Y.X.; Zhang, T.; Fu, S.P.; Hong, H.; Cheng, Y.; Xu, H.X.; Jing, X.Y.; Yu, M.L.; Zhu, B.M. Electroacupuncture reduces body weight by regulating fat browning-related proteins of adipose tissue in HFD-induced obese mice. Front. Psychiatry, 2019, 10, 353.
[http://dx.doi.org/10.3389/fpsyt.2019.00353] [PMID: 31244685]
[30]
Asamoto, S.; Takeshige, C. Activation of the satiety center by auricular acupuncture point stimulation. Brain Res. Bull., 1992, 29(2), 157-164.
[http://dx.doi.org/10.1016/0361-9230(92)90021-O] [PMID: 1525671]
[31]
Rosinger, A.Y.; Lawman, H.G.; Akinbami, L.J.; Ogden, C.L. The role of obesity in the relation between total water intake and urine osmolality in US adults, 2009-2012. Am. J. Clin. Nutr., 2016, 104(6), 1554-1561.
[http://dx.doi.org/10.3945/ajcn.116.137414] [PMID: 27935519]
[32]
Annamari, S.; Reetta, V.; Reija, P.; Marja, O.; Mikko, H. Surfactant protein D modulates levels of IL-10 and TNF-a in intrauterine compartments during lipopolysaccharide-induced preterm birth. Cytokine, 2012, 2012(60), 423-430.
[33]
Rai, A.K.; Jaiswal, N.; Maurya, C.K.; Sharma, A.; Ahmad, I.; Ahmad, S.; Gupta, A.P.; Gayen, J.R.; Tamrakar, A.K. Fructose-induced AGEs-RAGE signaling in skeletal muscle contributes to impairment of glucose homeostasis. J. Nutr. Biochem., 2019, 71, 35-44.
[http://dx.doi.org/10.1016/j.jnutbio.2019.05.016] [PMID: 31272030]
[34]
Fletcher, J.A.; Deja, S.; Satapati, S.; Fu, X.; Burgess, S.C.; Browning, J.D. Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver. JCI Insight, 2019, 5127737
[http://dx.doi.org/10.1172/jci.insight.127737] [PMID: 31012869]
[35]
Kim, M.H.; Shin, H.J.; Lim, S.J.; Park, J.S.; Lee, S.S.; Song, I.S.; Shin, J.G. Inter-individual variability in OCT1 expression and its relationship with OCT1 genotype in liver samples from a Korean population. Drug Metab. Pharmacokinet., 2012, 27(5), 530-535.
[http://dx.doi.org/10.2133/dmpk.DMPK-11-RG-109] [PMID: 22498645]
[36]
Bi, Y.A.; Costales, C.; Mathialagan, S.; West, M.; Eatemadpour, S.; Lazzaro, S.; Tylaska, L.; Scialis, R.; Zhang, H.; Umland, J.; Kimoto, E.; Tess, D.A.; Feng, B.; Tremaine, L.M.; Varma, M.V.S.; Rodrigues, A.D. Quantitative contribution of six major transporters to the hepatic uptake of drugs: ‘SLC-phenotyping’ using primary human hepatocytes. J. Pharmacol. Exp. Ther., 2019, 370(1), 72-83.
[http://dx.doi.org/10.1124/jpet.119.257600] [PMID: 30975793]
[37]
Lepist, E.I.; Zhang, X.X.; Hao, J.; Huang, J.; Kosaka, A.; Birkus, G.; Murray, B.P.; Bannister, R.; Cihlar, T.; Huang, Y.; Ray, A.S. OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat. Kidney Int., 2014, 86, 350-357.
[http://dx.doi.org/10.1038/ki.2014.66] [PMID: 24646860]
[38]
Ellis, L.C.; Hawksworth, G.M.; Weaver, R.J. ATP-dependent transport of statins by human and rat MRP2/Mrp2. Toxicol. Appl. Pharmacol., 2013, 269(2), 187-194.
[http://dx.doi.org/10.1016/j.taap.2013.03.019] [PMID: 23562342]
[39]
Jetter, A.; Kullak-Ublick, G.A. Drugs and hepatic transporters: A review. Pharmacol. Res., 2019. 104234 Epub ahead of print
[http://dx.doi.org/10.1016/j.phrs.2019.04.018] [PMID: 31004787]
[40]
Kux, L. Draft guidance for industry on drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations; availability. Fed. Regist., 2012, 3958, 9946-9947.
[41]
Shen, H.; Scialis, R.J.; Lehman-McKeeman, L. Xenobiotic transporters in the kidney: Function and role in toxicity. Semin. Nephrol., 2019, 39(2), 159-175.
[http://dx.doi.org/10.1016/j.semnephrol.2018.12.010] [PMID: 30827339]
[42]
Momper, J.D.; Yang, J.; Gockenbach, M.; Vaida, F.; Nigam, S.K. Dynamics of organic anion transporter-mediated tubular secretion during postnatal human kidney development and maturation. Clin. J. Am. Soc. Nephrol., 2019, 14(4), 540-548.
[http://dx.doi.org/10.2215/CJN.10350818] [PMID: 30885911]
[43]
Ma, L.; Qin, Y.; Shen, Z.; Bi, H.; Hu, H.; Huang, M.; Zhou, H.; Yu, L.; Jiang, H.; Zeng, S. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2. J. Ethnopharmacol., 2015, 172(72), 430-435.
[http://dx.doi.org/10.1016/j.jep.2015.07.011] [PMID: 26183576]
[44]
Zhu, P.; Ye, Z.; Guo, D.; Xiong, Z.; Huang, S.; Guo, J.; Zhang, W.; Polli, J.E.; Zhou, H.; Li, Q.; Shu, Y. Irinotecan alters the disposition of morphine via inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2). Pharm. Res., 2018, 35(12), 243.
[http://dx.doi.org/10.1007/s11095-018-2526-y] [PMID: 30361780]
[45]
Nishizawa, K.; Yoda, N.; Morokado, F.; Komori, H.; Nakanishi, T.; Tamai, I. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia. PLoS One, 2019, 14(4)e0214862
[http://dx.doi.org/10.1371/journal.pone.0214862] [PMID: 30951542]
[46]
Poruba, M.; Matuskova, Z.; Hüttl, M.; Malinska, H.; Oliyarnyk, O.; Markova, I.; Gurska, S.; Kazdova, L.; Vecera, R. Fenofibrate decreases hepatic p-glycoprotein in a rat model of hereditary hypertriglyceridemia. Front. Pharmacol., 2019, 10, 56.
[http://dx.doi.org/10.3389/fphar.2019.00056] [PMID: 30787874]
[47]
Barik, S.; Saini, M.; Rana, M.; Gupta, P.K. Multidrug resistance protein 4 (MRP4) is expressed as transcript variants in both Gallus domesticus and Gyps himalyanesis. Gene, 2019, 689, 172-182.
[http://dx.doi.org/10.1016/j.gene.2018.12.014] [PMID: 30562604]
[48]
Müller, J.; Keiser, M.; Drozdzik, M.; Oswald, S. Expression, regulation and function of intestinal drug transporters: An update. Biol. Chem., 2017, 398(2), 175-192.
[http://dx.doi.org/10.1515/hsz-2016-0259] [PMID: 27611766]
[49]
Shu, R.; Wang, C.; Meng, Q.; Liu, Z.; Wu, J.; Sun, P.; Sun, H.; Ma, X.; Huo, X.; Liu, K. Resveratrol enhances the protective effects of JBP485 against indomethacin-induced rat intestinal damage in vivo and vitro through up-regulating oligopeptide transporter 1 (Pept1). Biomed. Pharmacother., 2019, 111(111), 251-261.
[http://dx.doi.org/10.1016/j.biopha.2018.12.084] [PMID: 30590313]
[50]
Ito, S.; Kusuhara, H.; Yokochi, M.; Toyoshima, J.; Inoue, K.; Yuasa, H.; Sugiyama, Y. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J. Pharmacol. Exp. Ther., 2012, 340(2), 393-403.
[http://dx.doi.org/10.1124/jpet.111.184986] [PMID: 22072731]
[51]
Ellis, L.C.; Hawksworth, G.M.; Weaver, R.J. ATP-dependent transport of statins by human and rat MRP2/Mrp2. Toxicol. Appl. Pharmacol., 2013, 269(2), 187-194.
[http://dx.doi.org/10.1016/j.taap.2013.03.019] [PMID: 23562342]


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 20
ISSUE: 9
Year: 2019
Page: [742 - 755]
Pages: 14
DOI: 10.2174/1389200220666190902125435
Price: $58

Article Metrics

PDF: 41
HTML: 6
EPUB: 1
PRC: 1